Murray A. Raskind, MD

JCP
Dysregulation of Noradrenergic Activity
Academic Highlights

November 8, 2024

Dysregulation of noradrenergic activity plays a key role in symptom presentation in major depressive disorder, schizophrenia, Alzheimer’s agitation, and PTSD. This article provides an expert panel’s consensus regarding the...
, , , et al
JCP
Article

May 25, 2016

One alpha-1 noradrenergic antagonist drug has shown promise in treating PTSD-related sleep disturbances and nightmares, but it has a short half-life. Could the long half-life version of this type...
, , , et al
JCP
Letter to the Editor

January 15, 2010

,
JCP
Letter to the Editor

November 15, 2006

, , , et al
JCP
Original Research

July 16, 2002

, , , et al
JCP
Letter to the Editor

August 31, 2000

,
JCP
Original Research

July 31, 2000

, , , et al
JCP
Article

June 1, 1999

JCP
Original Research

May 1, 1999

, , , et al
JCP
Article

May 1, 1998

JCP
Article

March 1, 1998

Consensus Report on XT Use in Practice

Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe